Showing results (181-190 of 317) with videos related to

Sort By:
Pageof 32
Blood|October 1, 2024
High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutationsZhuoer Xie, Jenna Fernandez, Terra Lasho, et al.
The New England Journal of Medicine|September 3, 2015
A Pilot Study of the Telomerase Inhibitor Imetelstat for MyelofibrosisAyalew Tefferi, Terra L Lasho, Kebede H Begna, et al.
Haematologica|August 30, 2023
Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapyZhuoer Xie, Terra Lasho, Arushi Khurana, et al.
International Journal of Dermatology|March 8, 2023
Cutaneous involvement in VEXAS syndrome: clinical and histopathologic findingsAlexander S Hines, Nessa A Mohandesi, Julia S Lehman, et al.
Leukemia Research|August 22, 2016
A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML)Farhad Ravandi, Ivana Gojo, Mrinal M Patnaik, et al.
Oncogene|April 8, 2023
Molecular characterization stratifies VQ myeloma cells into two clusters with distinct risk signatures and drug responsesEvan Flietner, Mei Yu, Govinda Poudel, et al.
Leukemia Research|July 18, 2018
Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblastsAbhishek A Mangaonkar, Naseema Gangat, Aref Al-Kali, et al.
Blood Advances|November 11, 2018
Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular modelsAnimesh Pardanani, Sahrish Shah, Francesco Mannelli, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|September 20, 2016
Vancomycin-resistant Enterococcus colonization and bloodstream infection: prevalence, risk factors, and the impact on early outcomes after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemiaMehrdad Hefazi, Moussab Damlaj, Hassan B Alkhateeb, et al.
British Journal of Cancer|June 24, 2020
Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathyKamal S Saini, Carlo Lanza, Marco Romano, et al.
Pageof 32